Anti-Inflammatory Biologics Global Market Report 2025

Description

Anti-inflammatory biologics are therapeutic drugs derived from living organisms that specifically target elements of the immune system to reduce inflammation. They are widely used to treat chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease by inhibiting cytokines or immune cells responsible for triggering inflammation.

The main drug classes of anti-inflammatory biologics include tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors, T-cell inhibitors, and others. Tumor necrosis factor inhibitors are biologic drugs that block the activity of tumor necrosis factor-alpha, a substance in the body that causes inflammation, helping to alleviate symptoms in autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease. These medications are administered via various routes, including oral, injection, intravenous, and subcutaneous methods. They are commonly used for applications such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, among others, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and more. The end users of these biologics include hospitals, clinics, home care settings, and research and academic institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-inflammatory biologics market research report is one of a series of new reports from The Business Research Company that provides anti-inflammatory biologics market statistics, including anti-inflammatory biologics global market size, regional shares, competitors with anti-inflammatory biologics market share, detailed anti-inflammatory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory biologics industry. The anti-inflammatory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-inflammatory biologics market size has grown strongly in recent years. It will grow from $108.11 billion in 2024 to $118.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the rising prevalence of arthritis, increased awareness of autoimmune diseases, the growing introduction of new biologics, expanding healthcare infrastructure, and a rise in regulatory approvals.

The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $166.28 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to the increasing adoption of biologics, rising demand for targeted therapies, growing patient preference for long-term remission, expanded use of biomarkers for disease monitoring, and the increasing demand for personalized medicine. Key trends expected during this period include advancements in biologic drug development, the emergence of oral biologics for inflammation, technology-driven drug delivery systems, progress in biosimilars, and improvements in diagnostic tools.

The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory biologics market. Arthritis involves inflammation or swelling in one or more joints, resulting in pain, stiffness, and limited movement, often worsening with age. The rise in arthritis cases is largely linked to increasing obesity rates, as excess weight adds stress to the joints, causing inflammation and degeneration. Anti-inflammatory biologics work by targeting specific parts of the immune system to reduce inflammation, slow joint damage, alleviate symptoms, and enhance physical function and quality of life for individuals with moderate to severe arthritis. For example, in March 2023, the UK's Office for Health Improvement and Disparities reported that in 2022, 17.6% of people aged 16 and older had a long-term musculoskeletal condition like arthritis or persistent back or joint issues, up from 17.0% in 2021. This growing prevalence of arthritis is driving market expansion.

Companies in the anti-inflammatory biologics market are developing advanced treatments such as interleukin-6 (IL-6) receptor antagonists to more precisely target chronic inflammatory diseases while minimizing side effects. IL-6 receptor antagonists are biologic drugs that inhibit the IL-6 receptor, reducing inflammation and immune response in conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US biotechnology firm, received FDA approval for Kevzara as the first biologic specifically indicated for patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor to decrease inflammation associated with PMR, a disease causing muscle pain and stiffness, mainly in older adults. Unlike traditional steroids, which carry risks like osteoporosis and diabetes with long-term use, Kevzara offers a targeted, steroid-sparing alternative that promotes better patient outcomes and long-term safety.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen's position in innovative treatments for serious illnesses by expanding its portfolio in rare and autoimmune diseases, accelerating growth, and extending its reach to more patients worldwide with first-in-class therapies. Horizon Therapeutics plc, based in Ireland, focuses on developing several anti-inflammatory biologics.

Major players in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, and Hansa Biopharma AB.

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-inflammatory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-inflammatory biologics market consists of sales of adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Inflammatory Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-inflammatory biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-inflammatory biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anti-inflammatory biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Tumor Necrosis Factor Inhibitors; Interleukin Inhibitors; B-Cell Inhibitors; T-Cell Inhibitors; Other Drug Classes
2) By Route Of Administration: Oral; Injection; Intravenous; Subcutaneous
3) By Application: Rheumatoid Arthritis; Inflammatory Bowel Disease; Psoriasis; Other Applications
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
5) By End-Users: Hospital; Clinics; Home Care Settings; Research And Academic Institutes
Subsegments:
1) By Tumor Necrosis Factor Inhibitors: Adalimumab; Infliximab; Etanercept; Golimumab; Certolizumab Pegol
2) By Interleukin Inhibitors: Interleukin-1 Inhibitors; Interleukin-6 Inhibitors; Interleukin -12 Or 23 Inhibitors; Interleukin -17 Inhibitors; Interleukin -23 Inhibitors
3) By B-Cell Inhibitors: Rituximab; Ocrelizumab; Ofatumumab
4) By T-Cell Inhibitors: Abatacept; Alefacept
5) By Other Drug Classes: Janus Kinase Inhibitors; Phosphodiesterase-4 Inhibitors; Sphingosine 1-Phosphate Receptor Modulators; Anti-IgE And Other Biologics
Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; AbbVie Inc; Sanofi S.A; Bristol-Myers Squibb; AstraZeneca PLC; Novartis AG; GSK plc; Eli Lilly and Company; Gilead Sciences Inc; Amgen Inc.; Regeneron Pharmaceuticals Inc; Biogen Inc.; UCB S.A; UCB S.A./N.V; Swedish Orphan Biovitrum AB; Almirall S.A.; Evotec SE; Hansa Biopharma AB.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r36924

1. Executive Summary

2. Anti-Inflammatory Biologics Market Characteristics

3. Anti-Inflammatory Biologics Market Trends And Strategies

4. Anti-Inflammatory Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Anti-Inflammatory Biologics Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Inflammatory Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Inflammatory Biologics Market Growth Rate Analysis
5.4. Global Anti-Inflammatory Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Inflammatory Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Inflammatory Biologics Total Addressable Market (TAM)

6. Anti-Inflammatory Biologics Market Segmentation

6.1. Global Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Necrosis Factor Inhibitors
Interleukin Inhibitors
B-Cell Inhibitors
T-Cell Inhibitors
Other Drug Classes
6.2. Global Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injection
Intravenous
Subcutaneous
6.3. Global Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rheumatoid Arthritis
Inflammatory Bowel Disease
Psoriasis
Other Applications
6.4. Global Anti-Inflammatory Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.5. Global Anti-Inflammatory Biologics Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Clinics
Home Care Settings
Research And Academic Institutes
6.6. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Tumor Necrosis Factor Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adalimumab
Infliximab
Etanercept
Golimumab
Certolizumab pegol
6.7. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Interleukin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interleukin -1 Inhibitors
Interleukin -6 Inhibitors
Interleukin -12 Or 23 Inhibitors
Interleukin -17 Inhibitors
Interleukin -23 Inhibitors
6.8. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of B-Cell Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rituximab
Ocrelizumab
Ofatumumab
6.9. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of T-Cell Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Abatacept
Alefacept
6.10. Global Anti-Inflammatory Biologics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Janus Kinase Inhibitors
Phosphodiesterase-4 Inhibitors
Sphingosine 1-Phosphate Receptor Modulators
Anti-IgE And Other Biologics

7. Anti-Inflammatory Biologics Market Regional And Country Analysis

7.1. Global Anti-Inflammatory Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Inflammatory Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Inflammatory Biologics Market

8.1. Asia-Pacific Anti-Inflammatory Biologics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Inflammatory Biologics Market

9.1. China Anti-Inflammatory Biologics Market Overview
9.2. China Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Inflammatory Biologics Market

10.1. India Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Inflammatory Biologics Market

11.1. Japan Anti-Inflammatory Biologics Market Overview
11.2. Japan Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Inflammatory Biologics Market

12.1. Australia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Inflammatory Biologics Market

13.1. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Inflammatory Biologics Market

14.1. South Korea Anti-Inflammatory Biologics Market Overview
14.2. South Korea Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Inflammatory Biologics Market

15.1. Western Europe Anti-Inflammatory Biologics Market Overview
15.2. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Inflammatory Biologics Market

16.1. UK Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Inflammatory Biologics Market

17.1. Germany Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Inflammatory Biologics Market

18.1. France Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Inflammatory Biologics Market

19.1. Italy Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Inflammatory Biologics Market

20.1. Spain Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Inflammatory Biologics Market

21.1. Eastern Europe Anti-Inflammatory Biologics Market Overview
21.2. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Inflammatory Biologics Market

22.1. Russia Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Inflammatory Biologics Market

23.1. North America Anti-Inflammatory Biologics Market Overview
23.2. North America Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Inflammatory Biologics Market

24.1. USA Anti-Inflammatory Biologics Market Overview
24.2. USA Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Inflammatory Biologics Market

25.1. Canada Anti-Inflammatory Biologics Market Overview
25.2. Canada Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Inflammatory Biologics Market

26.1. South America Anti-Inflammatory Biologics Market Overview
26.2. South America Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Inflammatory Biologics Market

27.1. Brazil Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Inflammatory Biologics Market

28.1. Middle East Anti-Inflammatory Biologics Market Overview
28.2. Middle East Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Inflammatory Biologics Market

29.1. Africa Anti-Inflammatory Biologics Market Overview
29.2. Africa Anti-Inflammatory Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Inflammatory Biologics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Inflammatory Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Inflammatory Biologics Market Competitive Landscape And Company Profiles

30.1. Anti-Inflammatory Biologics Market Competitive Landscape
30.2. Anti-Inflammatory Biologics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Inflammatory Biologics Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb
31.2. AstraZeneca PLC
31.3. Novartis AG
31.4. GSK plc
31.5. Eli Lilly and Company
31.6. Gilead Sciences Inc
31.7. Amgen Inc.
31.8. Regeneron Pharmaceuticals Inc
31.9. Biogen Inc.
31.10. UCB S.A
31.11. UCB S.A./N.V
31.12. Swedish Orphan Biovitrum AB
31.13. Almirall S.A.
31.14. Evotec SE
31.15. Hansa Biopharma AB

32. Global Anti-Inflammatory Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Inflammatory Biologics Market

34. Recent Developments In The Anti-Inflammatory Biologics Market

35. Anti-Inflammatory Biologics Market High Potential Countries, Segments and Strategies

35.1 Anti-Inflammatory Biologics Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Inflammatory Biologics Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Inflammatory Biologics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer